Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 240

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 240
---
 by confidentiality agreements with our employees, consultants, collaborators and others, including certain service providers.
We also have invention or patent assignment agreements with our current employees and certain consultants. Nonetheless, our employees
and consultants may breach these agreements, and we may not have adequate remedies for the breach. Our trade secrets may otherwise become
known or be independently discovered by competitors or could be developed by a person not bound by an invention assignment agreement
with us, in which case we may have no rights to use the applicable invention.

We may face additional competition outside
of the U.S. as a result of a lack of patent coverage in some territories and differences in patent prosecution and enforcement laws in
foreign counties. 

Filing, prosecuting, defending
and enforcing patents on our proprietary formulations throughout the world is extremely expensive. We do not currently have patent protection
outside of the U.S. that covers any of our proprietary formulations or other assets that we are currently pursuing. Competitors may use
our technologies to develop their own products in jurisdictions where we have not obtained patent protection.

Even if the international patent
applications we have filed or may in the future file are issued or approved, it is likely that the scope of protection provided by such
patents would be different from, and possibly less than, the scope provided by corresponding U.S. patents. As a result, patent rights
we are able to obtain may not be sufficient to prevent generic competition. Further, the extent of our international market opportunity
may be dependent upon the enforcement of patent rights in various other countries. A number of countries in which we could file patent
applications have a history of weak enforcement and/or compulsory licensing of intellectual property rights. Moreover, the legal systems
of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patents and other intellectual
property protection, particularly those relating to biotechnology and/or pharmaceuticals, which would make it difficult for us to stop
a third party from infringing any of our intellectual property rights. Moreover, attempting to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business.

 36 

Our products, drug candidates and compounded
formulations and technologies could potentially conflict with the rights of others.

The preparation or sale of our
products, drug candidates and compounded formulations and use of our technologies may infringe on the patent or other intellectual property
rights of others. If our products infringe or conflict with the patent or other intellectual property rights of others,